GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » E10

Benitec Biopharma (Benitec Biopharma) E10 : $-90.89 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Benitec Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-90.89 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-21), Benitec Biopharma's current stock price is $10.47. Benitec Biopharma's E10 for the quarter that ended in Mar. 2024 was $-90.89. Benitec Biopharma's Shiller PE Ratio of today is .


Benitec Biopharma E10 Historical Data

The historical data trend for Benitec Biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma E10 Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -89.32 -90.89

Competitive Comparison of Benitec Biopharma's E10

For the Biotechnology subindustry, Benitec Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Shiller PE Ratio falls into.



Benitec Biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Benitec Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.64/131.7762*131.7762
=-1.640

Current CPI (Mar. 2024) = 131.7762.

Benitec Biopharma Quarterly Data

per share eps CPI Adj_EPS
201312 0.000 98.326 0.000
201406 -2.642 100.560 -3.462
201412 0.000 99.070 0.000
201503 -1.760 99.621 -2.328
201506 -10.403 100.684 -13.616
201509 -235.620 100.392 -309.280
201512 -11.504 99.792 -15.191
201603 -5.088 100.470 -6.673
201606 -8.834 101.688 -11.448
201609 15.559 101.861 20.128
201612 -4.605 101.863 -5.957
201703 -0.368 102.862 -0.471
201706 -2.907 103.349 -3.707
201709 -56.018 104.136 -70.887
201712 -3.325 104.011 -4.213
201803 -3.027 105.290 -3.788
201806 -42.800 106.317 -53.049
201809 0.000 106.507 0.000
201812 9.914 105.998 12.325
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 -22.780 108.329 -27.710
201912 -34.000 108.420 -41.324
202003 -33.320 108.902 -40.319
202006 -46.580 108.767 -56.434
202009 -41.650 109.815 -49.979
202012 -12.920 109.897 -15.492
202103 -13.940 111.754 -16.437
202106 -8.328 114.631 -9.574
202109 -10.540 115.734 -12.001
202112 -10.030 117.630 -11.236
202203 -6.800 121.301 -7.387
202206 -10.541 125.017 -11.111
202209 -7.980 125.227 -8.397
202212 -3.340 125.222 -3.515
202303 -2.670 127.348 -2.763
202306 -2.832 128.729 -2.899
202309 -2.760 129.860 -2.801
202312 -2.640 129.419 -2.688
202403 -1.640 131.776 -1.640

Add all the adjusted EPS together and divide 10 will get our e10.


Benitec Biopharma  (NAS:BNTC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Benitec Biopharma E10 Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000